Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.54 |
| ▸ | FGFR4 | P22455 | 9/20 | 0.54 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT4 | P35916 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ROS1 | P08922 | 2/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16072052 | 0.89 | FGFR4 (0.69) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL16367921 | 0.73 | FGFR4 (0.75) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL18612797 | 0.73 | FGFR4 (0.62) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL22420120 | 0.72 | FGFR4 (0.80) | FGFR4PTK2ALDH1A1 | |
| SCHEMBL24690432 | 0.72 | FGFR4 (0.69) | FGFR1FGFR4FGFR2FGFR3MAPK3 | |
| SCHEMBL5619571 | 0.71 | FGFR1 (1.00) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL24690431 | 0.70 | FGFR4 (0.51) | FGFR4PTK2MAPK3 | |
| SCHEMBL15434011 | 0.70 | FGFR4 (1.00) | FGFR1FGFR4FGFR2FGFR3EGFR | |
| SCHEMBL8804831 | 0.69 | FGFR1 (0.55) | FGFR1 | |
| SCHEMBL18857581 | 0.68 | MAPK3 (0.81) | PTK2EGFRKDRMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189794-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189794-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | FGFR1 3322/4885FGFR4 2623/4885PTK2 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.